Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.
Melissa A. Wilson, MD, PhD
Advertisement
Articles by Melissa A. Wilson, MD, PhD
Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.
Melissa A. Wilson, MD, PhD, discusses how targeted therapies and combination protocols are revolutionizing the treatment paradigm of advanced melanoma.
Advertisement
Latest Updated Articles
Dr. Wilson on Long-term Data With Dabrafenib Plus Trametinib in MelanomaPublished: July 27th 2017 | Updated:
Dr. Wilson on Choosing Between BRAF/MEK Therapies for Patients With MelanomaPublished: August 16th 2017 | Updated:
Targeted Therapies, Combination Protocols Are Revolutionizing Treatment for Advanced MelanomaPublished: July 14th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5